Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
andrea.botticelli@uniroma1.it
Andrea Botticelli
Professore Associato
Struttura:
DIPARTIMENTO DI SCIENZE RADIOLOGICHE, ONCOLOGICHE E ANATOMO-PATOLOGICHE
E-mail:
andrea.botticelli@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
ONCOTARGET
2017
Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong
JOURNAL OF THORACIC DISEASE
2017
Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients
JOURNAL OF CLINICAL ONCOLOGY
2017
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting
JOURNAL OF CELLULAR PHYSIOLOGY
2017
Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis
HPB
2017
Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients
PHARMACOGENOMICS
2017
Pre-treatment evaluation of 5-fluorouracil degradation rate. association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort
ONCOTARGET
2016
CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy
THE EURASIAN JOURNAL OF MEDICINE
2016
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer
ANTI-CANCER DRUGS
2016
Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer
ONCOTARGET
2016
Degradation rate of 5-fluorouracil in metastatic colorectal cancer. A new predictive outcome biomarker?
PLOS ONE
2016
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX
ANTI-CANCER DRUGS
2016
F295-fluorouracil degradation rate (5-FU-DR) could predict toxicity in breast cancer patients treated with capecitabine
ANNALS OF ONCOLOGY
2016
Genotype–phenotype correlations in 5-fluorouracil metabolism. a candidate DPYD haplotype to improve toxicity prediction
PHARMACOGENOMICS JOURNAL
2015
Effect of MTHFR polymorphisms on gastrointestinal cancer risk in Italy
WORLD JOURNAL OF ONCOLOGY
2015
Electrochemotherapy treatment of cutaneous metastases from breast cancer
THE AMERICAN SURGEON
2015
Positive impact of elastography in breast cancer diagnosis: an institutional experience
JOURNAL OF ULTRASOUND
2015
FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
WORLD JOURNAL OF ONCOLOGY
2015
« prima
< precedente
1
2
3
4
5
6
7
8
9
Progetti di Ricerca
Window therapy with CDK 4/6 inhibitors in head and neck cancer patients treated with immunotherapy
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma